Yamashita, Toshinari
Sohn, Joo Hyuk
Tokunaga, Eriko
Niikura, Naoki
Park, Yeon Hee
Lee, Keun Seok
Chae, Yee Soo
Xu, Binghe
Wang, Xiaojia
Im, Seock-Ah
Li, Wei
Lu, Yen-Shen
Aguilar, Cecilia Orbegoso
Nishijima, Soichiro
Nishiyama, Yuji
Sugihara, Masahiro
Modi, Shanu
Tsurutani, Junji http://orcid.org/0000-0002-6260-6943
Clinical trials referenced in this document:
Documents that mention this clinical trial
Trastuzumab deruxtecan versus treatment of physician’s choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study
https://doi.org/10.1007/s12282-024-01600-7
US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer
https://doi.org/10.1200/jco.22.02447
Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR+) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04.
https://doi.org/10.1200/jco.2023.41.16_suppl.1020
Pooled analysis on characteristics of nausea and vomiting in patients receiving trastuzumab deruxtecan (T-DXd) in clinical studies.
https://doi.org/10.1200/jco.2024.42.16_suppl.12118
Funding for this research was provided by:
Daiichi Sankyo in collaboration with AstraZeneca
Article History
Received: 29 March 2024
Accepted: 25 May 2024
First Online: 17 June 2024
Declarations
:
: Toshinari Yamashita received lecture fees or honoraria from Chugai, Daiichi Sankyo, Pfizer, Eli Lilly, and Kyowa Kirin; and received lecture fees or honoraria from Chugai, Daiichi Sankyo, Pfizer, Ono Pharma, Eisai, and AstraZeneca. Eriko Tokunaga received lecture fees or honoraria from Eli Lilly, Daiichi Sankyo, and AstraZeneca. Naoki Niikura received lecture fees or honoraria from AstraZeneca, Pfizer, Chugai, Daiichi Sankyo, Eli Lilly, and MSD; received annual remuneration from AstraZeneca; received lecture fees or honoraria from Chugai, Daiichi Sankyo, Pfizer, Mochida, and Novartis; and received value of scholarships from Chugai and Eisai. Seock-Ah Im received lecture fees or honoraria from AstraZeneca, Eisai, Daewoong Pharm, Daiichi Sankyo, Pfizer, Roche, and Boryung Pharmaceutical. Yen-Shen Lu received lecture fees or honoraria as grant support for investigator-initiated trials from Novartis, AstraZeneca, and MSD; received travel support from Novartis to attend the SABCS meeting in 2022, from Novartis to attend the ESMO Asia meeting in 2022, from MSD to attend the ASCO meeting in 2023, and from Daiichi Sankyo to attend the ESMO meeting in 2023. Shanu Modi received lecture fees or honoraria from Daiichi Sankyo, Eli Lilly, Genentech, MacroGenics, GlaxoSmithKline, Seagen, Gilead Sciences, and AstraZeneca; and received research funds from Novartis, Genentech, AstraZeneca, Seagen, Daiichi Sankyo, and Duality Bio (all research funds of Shanu Modi were given to the institution). Junji Tsurutani received lecture fees or honoraria from Daiichi Sankyo, Eli Lilly, and Kyowa Kirin; and received lecture fees or honoraria from Showa University, Eli Lilly, Eisai, West Japan Oncology Group, and Otsuka. Soichiro Nishijima, Yuji Nishiyama, and Masahiro Sugihara are employees of Daiichi Sankyo. Cecilia Orbegoso Aguilar is an employee of Daiichi Sankyo and received annual share profits from Daiichi Sankyo.
: The study was conducted in accordance with the ethical standards of the Declaration of Helsinki, the International Council for Harmonization Good Clinical Practice guidelines and other local regulations, and was approved by the Institutional Review Board at each study site.
: Informed consent was obtained from all individual participants included in the study. This article does not contain any studies with animals performed by any of the authors.